STIM VS SLGL Stock Comparison

Performance

STIM
10/100

STIM returned -72.04% in the last 12 months. Based on SPY's performance of -13.39%, its performance is below average giving it a score of 10 of 100.

SLGL
10/100

SLGL returned -70.49% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

STIM
90/100

5 analysts offer 12-month price targets for STIM. Together, they have an average target of 8, the most optimistic target put STIM at 8 within 12-months and the most pessimistic has STIM at 8.

SLGL
88/100

4 analysts offer 12-month price targets for SLGL. Together, they have an average target of 21, the most optimistic target put SLGL at 21 within 12-months and the most pessimistic has SLGL at 21.

Sentiment

STIM
74/100

STIM had a bullish sentiment score of 74.22% across Twitter and StockTwits over the last 12 months. It had an average of 3.11 posts, 0.22 comments, and 0.44 likes per day.

SLGL

"Sentiment" not found for SLGL

Technicals

STIM
64/100

STIM receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

SLGL
36/100

SLGL receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

Earnings

STIM
24/100

STIM has missed earnings 4 times in the last 20 quarters.

SLGL
10/100

SLGL has missed earnings 7 times in the last 20 quarters.

Profit

STIM
10/100

Out of the last 20 quarters, STIM has had 0 profitable quarters and has increased their profits year over year on 0 of them.

SLGL
19/100

Out of the last 20 quarters, SLGL has had 4 profitable quarters and has increased their profits year over year on 3 of them.

Volatility

STIM
33/100

STIM has had a lower than average amount of volatility over the last 12 months giving it a score of 33 of 100.

SLGL
41/100

SLGL has had a lower than average amount of volatility over the last 12 months giving it a score of 41 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Neuronetics, Inc. Common Stock Summary

Nasdaq / STIM

Healthcare

Medical - Diagnostics & Research

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Sol-Gel Technologies Ltd. Ordinary Shares Summary

Nasdaq / SLGL

Healthcare

Biotechnology

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Power up your portfolio